Magnesium and Vitamin D Supplementation and Cardiometabolic Outcomes

Parathyroid Hormone and Cardiometabolic Outcomes in Obesity: Role of Magnesium and Vitamin D Supplementation

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03134417

Enrollment

109

Registered

2017-05-01

Start date

2016-02-01

Completion date

2021-06-01

Last updated

2021-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk Factor, Magnesium Deficiency, Overweight and Obesity, Vitamin D Deficiency

Brief summary

The purpose of this study is to investigate the effects of a combined vitamin D and magnesium supplementation on parathyroid hormone and cardiometabolic health in persons living with obesity.

Detailed description

Individuals living with obesity are at a higher risk of cardiometabolic abnormalities and high circulating parathyroid hormone. There is evidence suggesting that vitamin D may play a role in cardiovascular health outcomes; however, the research is currently inconclusive. Magnesium is a cofactor of vitamin D metabolism, and the prevalence of concurrent vitamin D and magnesium deficiency is high. This study aims to investigate the effect of vitamin D and magnesium supplements in individuals who are overweight and obese on parathyroid hormone and cardiometabolic health.

Interventions

DIETARY_SUPPLEMENTVitamin D and magnesium

Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.

DIETARY_SUPPLEMENTVitamin D

Daily vitamin D supplements are given to participants daily for 12 weeks.

DIETARY_SUPPLEMENTPlacebo

Daily placebo are given to participants daily for 12 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI range 25-40 kg/m2 * 30-70 years of age

Exclusion criteria

* Presence of any acute illness in the past month * Pre-existing chronic medical conditions or medications know to influence energy, vitamin D, magnesium and calcium metabolism, levels of blood glucose, lipids and blood pressure * Individuals taking vitamin D and magnesium supplement greater than the Recommended Daily allowance * Participants taking any medications or have disease known to influence calcium or bone metabolism

Design outcomes

Primary

Measure	Time frame
Serum parathyroid hormone	12 weeks

Secondary

Measure	Time frame
Inflammatory cytokines	12 weeks
Lipid profile	12 weeks
Blood pressure	12 weeks
Serum osteocalcin	12 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026